Stocktoria
Crinetics Pharmaceuticals, Inc. CRNX
Crinetics Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $1.0M | $4.0M | $4.7M | $1.1M | $71,000 | $1.2M | $2.4M | $2.0M |
| R&D expense | $332.1M | $240.2M | $168.5M | $130.2M | $84.3M | $57.0M | $41.5M | $24.5M | $9.2M |
| SG&A expense | $191.3M | $99.7M | $58.1M | — | — | — | — | — | — |
| Operating income | -$516.8M | -$338.9M | -$222.6M | -$167.9M | -$107.7M | -$75.0M | -$53.8M | -$28.7M | -$9.1M |
| Interest expense | — | — | — | — | — | — | — | — | $8,000 |
| Income tax | $180,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$465.3M | -$298.4M | -$214.5M | -$163.9M | -$107.6M | -$73.8M | -$50.4M | -$27.1M | -$9.2M |
| EPS (diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | — | — | — |
| Operating cash flow | -$377.9M | -$230.2M | -$168.6M | -$115.2M | -$88.6M | -$62.0M | -$46.4M | -$19.5M | -$9.5M |
| Free cash flow | -$383.7M | -$234.0M | -$173.3M | -$116.9M | -$89.0M | -$62.2M | -$46.9M | -$20.5M | -$9.8M |
| Cash & equivalents | $101.5M | $264.5M | $54.9M | $32.7M | $200.7M | $93.1M | $40.3M | $45.0M | $14.2M |
| Inventory | $2.0M | $0 | — | — | — | — | — | — | — |
| Total assets | $1.1B | $1.4B | $635.4M | $352.2M | $351.0M | $183.4M | $130.4M | $171.4M | $15.6M |
| Total liabilities | $134.2M | $109.8M | $96.2M | $35.8M | $19.1M | $14.5M | $13.2M | $11.2M | $920,000 |
| Shareholders' equity | $992.1M | $1.3B | $539.1M | $316.3M | $331.9M | $168.9M | $117.1M | $160.2M | -$15.0M |
Growth · year-over-year · Revenue CAGR 18%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +640.7% | -74.1% | -15.3% | +339.4% | +1418.3% | -94.0% | -50.9% | +18.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.